becaplermin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
platelet-derived growth factor 4925 165101-51-9

Description:

MoleculeDescription

Synonyms:

  • becaplermin
  • rhPDGF-BB
  • RWJ-60235
  • RWJ 60235
  • regranex
A recombinant human platelet-derived growth factor B-chain dimer used to promote WOUND HEALING by stimulating PHYSIOLOGIC ANGIOGENESIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 16, 1997 FDA OMJ PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wound complication 202.08 89.95 31 305 4732 90623379
Toe amputation 106.68 89.95 16 320 2053 90626058
Osteomyelitis 91.39 89.95 21 315 27825 90600286

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wound complication 261.33 70.87 42 466 2645 42618182
Osteomyelitis 165.17 70.87 39 469 18184 42602643
Toe amputation 107.45 70.87 20 488 2909 42617918
Cellulitis 82.91 70.87 30 478 61555 42559272

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Wound complication 300.94 51.49 50 777 6127 110582345
Osteomyelitis 201.69 51.49 48 779 36552 110551920
Toe amputation 182.35 51.49 31 796 4307 110584165
Cellulitis 115.62 51.49 41 786 125975 110462497
Application site infection 95.20 51.49 11 816 84 110588388
Wound infection staphylococcal 74.46 51.49 14 813 3395 110585077
Application site pain 73.67 51.49 15 812 5484 110582988
Inappropriate schedule of product administration 52.55 51.49 27 800 203610 110384862

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AD08 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Other agents for local oral treatment
ATC D03AX06 DERMATOLOGICALS
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
CICATRIZANTS
Other cicatrizants
FDA CS M0017024 Platelet-Derived Growth Factor
MeSH PA D000925 Anticoagulants
MeSH PA D006133 Growth Substances
MeSH PA D006401 Hematologic Agents
MeSH PA D043925 Angiogenesis Inducing Agents
FDA EPC N0000175885 Human Platelet-derived Growth Factor
CHEBI has role CHEBI:49201 anti-ulcer drug

Related Drugs by ATC class:

A01AD Other agents for local oral treatment 5 drugs
acetylsalicylic acidadrenaloneamlexanoxbenzydamineepinephrine
D03AX Other cicatrizants 9 drugs
beremagene geperpaveccalcium pantothenatecrilanomerdexpanthenolenoxolonehyaluronic acidsodium chloritetrafermintrolamine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Neuropathic diabetic ulcer - foot indication 201251005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Platelet-derived growth factor receptor Kinase AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D03065 KEGG_DRUG
4021101 VUID
N0000148557 NUI
4021101 VANDF
CHEBI:749433 CHEBI
CHEMBL1201556 ChEMBL_ID
DB00102 DRUGBANK_ID
115238 RXNORM
11521 MMSL
4248 MMSL
007329 NDDF
108936003 SNOMEDCT_US
386940001 SNOMEDCT_US
C0379135 UMLSCUI
D000077214 MESH_DESCRIPTOR_UI
7454 INN_ID
1B56C968OA UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Regranex Gel 0.01% HUMAN PRESCRIPTION DRUG LABEL 1 85822-734 GEL 0.10 mg TOPICAL BLA 20 sections